Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabigatran Etexilate (P-gp Transporter Substrate) in Healthy Postmenopausal Female Volunteers

Next Previous
Search
Trial Profile

A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabigatran Etexilate (P-gp Transporter Substrate) in Healthy Postmenopausal Female Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camizestrant (Primary) ; Celecoxib (Primary) ; Dabigatran etexilate (Primary) ; Midazolam (Primary) ; Omeprazole (Primary)
  • Indications Breast cancer; Cardiomyopathies; Cardiovascular disorders; Deep vein thrombosis; Embolism; Gastrointestinal haemorrhage; Pulmonary embolism; Stroke; Vascular disorders; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 11 Jan 2023 Status changed from recruiting to completed.
    • 14 Nov 2022 Planned End Date changed from 1 Dec 2022 to 28 Nov 2022.
    • 14 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 28 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top